(NYSE: HAE) Haemonetics's forecast annual revenue growth rate of 3.65% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 11.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.91%.
Haemonetics's revenue in 2026 is $1,318,275,000.On average, 12 Wall Street analysts forecast HAE's revenue for 2026 to be $62,178,666,300, with the lowest HAE revenue forecast at $60,040,984,200, and the highest HAE revenue forecast at $64,920,475,950. On average, 12 Wall Street analysts forecast HAE's revenue for 2027 to be $65,478,132,150, with the lowest HAE revenue forecast at $62,968,679,250, and the highest HAE revenue forecast at $68,824,069,350.
In 2028, HAE is forecast to generate $69,846,439,050 in revenue, with the lowest revenue forecast at $66,361,087,800 and the highest revenue forecast at $73,796,503,800.